- ►diabetesjournals.org J Mei, LS Holst, TR Landström, C Holm, D … - Diabetes, 2002 - Am Diabetes Assoc Cyclic nucleotide phosphodiesterase (PDE) 3B plays an important role in the
antilipolytic action of insulin and, thereby, the release of fatty acids from
adipocytes. Increased concentrations of circulating fatty acids as a result ... Cited by 12 - Related articles - BL Direct - All 5 versions
[CITATION] Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase Type 3B …
E Degerman, TR Landstrom, J Wijkander, LS … - Abstract| PDF (286 K)| View Record in Scopus| Cited … Cited by 2 - Related articles
- ►nih.gov [PDF] TR Landström, J Mei, M Karlsson, V … - Biochemical Journal, 2000 - pubmedcentral.nih.gov We have used murine 3T3-L1 cells, which differentiate in culture and acquire
morphological and biochemical features of mature adipocytes, as a model for
studying the expression of cyclic- nucleotide phosphodiesterase (PDE) 3B ... Cited by 48 - Related articles - BL Direct - All 4 versions
- ►eje-online.org [PDF] Y Tang, H Osawa, H Onuma, M Hasegawa, T … - European Journal of Endocrinology, 2001 - EFES Objective: Phosphodiesterase (PDE) 3B is a key enzyme involved in the
anti-lipolytic action of insulin in adipocytes. PDE3B activation results in a
reduced output of free fatty acids (FFA), whereas elevated serum FFA is ... Cited by 10 - Related articles - BL Direct - All 7 versions
C Schoelch, J Kuhlmann, M Gossel, G Mueller … - Diabetes, 2004 - Am Diabetes Assoc Increased supply of fatty acids to muscle and liver is causally involved in the
insulin resistance syndrome. Using a tissue microdialysis technique in Wistar
and Zucker fatty (ZF) rats, we determined tissue glycerol levels as a ... Cited by 11 - Related articles - BL Direct - All 4 versions
T Lei, W Xie, J Han, BE Corkey, JA Hamilton, … - Obesity, 2004 - nature.com Research Methods and Procedures: 3T3-L1 adipocytes were pretreated with
octanoate for various incubation periods. After the removal of exogenous FAs,
cells were incubated with different lipolytic agonists. To determine the ... Related articles
WF Nieuwenhuizen, AM Haveres, JJ Emeis - US Patent App. 10/592,994, 2005 - Google Patents US 20070207983A1 (19) United States (12) Patent Application Publication GO) Pub.
NO.: US 2007/0207983 Al Nieuwenhuizen et al. (43) Pub. Date: Sep. 6,2007 (54)
USE OF SPHINGOLIPIDS IN THE TREATMENT AND PREVENTION OF TYPE 2 DIABETES ... Related articles - All 7 versions
H Liu, J RongTang, E Degerman, VC … - Phosphodiesterase methods and protocols, 2005 - Springer Summary We describe techniques for identifying functional promoter elements in
the 5′-flanking region of the murine cyclic nucleotide phosphodiesterase 3B
(mPDE3B) gene. The 5′-flanking region of the mPDE3B gene was cloned and ... Related articles - All 4 versions
A Oknianska, E Zmuda-Trzebiatowska, V … - Biochemical and Biophysical Research …, 2007 - Elsevier Phosphodiesterase 3B (PDE3B), is known to play an important role in acute
insulin and cAMP-mediated regulation of lipid metabolism, and PDE4 are the main
PDE types expressed in adipocytes. Here, we show that members of all PDE4 ... Related articles - All 4 versions
- ►endojournals.org L Akesson, B Ahren, G Edgren, E Degerman - Endocrinology, 2005 - Endocrine Soc The neuropeptides pituitary adenylate cyclase-activating polypeptide (PACAP) and
vasoactive intestinal polypeptide (VIP) are structurally and functionally
related. Their actions have been shown to be mediated by three different ... Cited by 13 - Related articles - All 4 versions
